Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- University of North Carolina, Chapel Hill
- Study ID
- NCT06405373
- Status
- Recruiting
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes type1
- Diabetes, Autoimmune
- Distress, Emotional
Eligibility Criteria
- Sex
- ALL
- Age
- 30 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ReCharge — BEHAVIORALReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
- TakeCharge — BEHAVIORALTakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
Study Details
This study is designed to compare two behavioral approaches to reduce diabetes distress ("the expected burdens, concerns, fears, and threats that arise from the challenges of living with diabetes") in adults with type 1 diabetes. At the study baseline, participants will be randomized to take part in one of two virtual, group-based interventions (the "Primary" intervention) utilizing either an emotions-focused or a problem-solving approach to reduce diabetes distress. After the initial intervention, participants will complete surveys to assess their response to the material. Participants who are determined to be "non-responders" (i.e., the Primary intervention was not effective) will be re-randomized to one of two "Supplementary" interventions, which will include individualized sessions to learn and/or practice strategies related to either the psychological or problem-solving approach.
Key Dates
- Start date
- Oct 1, 2024
- Status verified
- Oct 2025
- Primary completion
- Sep 15, 2027
- Completion
- Sep 15, 2027
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: ReChargeParticipants randomized to ReCharge will participate in an emotions-focused intervention facilitated by a mental health professional.
- Experimental: TakeChargeParticipants randomized to TakeCharge will participate in a problem-solving focused intervention facilitated by a diabetes care professional.
Primary Outcome Measure
Change in Total Diabetes Distress (T1-DDS Total Score) [ Time Frame: Baseline, Interim (6 weeks), Endpoint (12 weeks) ]
Central Contacts
- Angela Fruik, MPH, RD919-962-6348
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Anna Kahkoska, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Chapel Hill, NC
Related Studies
- Early Check: Expanded Screening in NewbornsEnrolling By Invitation · RTI International · Research Triangle Park, North Carolina
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- Rare and Atypical Diabetes NetworkRecruiting · University of South Florida · Aurora, Colorado
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesPHASE3 · Recruiting · vTv Therapeutics · Scottsdale, Arizona